Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page
- Check2 days agoChange DetectedAdded a government funding notice about NIH operations and updated the site revision to v3.4.1, replacing v3.4.0.SummaryDifference0.1%

- Check9 days agoChange DetectedGlossary toggle is now visible; metadata labels have standardized capitalization (No FEAR Act Data). The revision tag has been updated from v3.3.4 to v3.4.0.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check45 days agoChange DetectedExpanded the study site locations with a broader set of recruitment sites across the United States and worldwide, and removed several previously listed locations.SummaryDifference4%

- Check67 days agoChange DetectedFooter revision label updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check74 days agoChange DetectedAdded notes clarifying that publications can be entered voluntarily and may be auto-filled from PubMed; a revision label v3.3.1 was added, replacing the former v3.2.0 wording.SummaryDifference0.2%

- Check81 days agoChange DetectedRemoved the government funding status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.